Shruti Naik, PhD, Damon Runyon Fellow, Rockefeller University 

I was recently asked by Lorraine Egan to serve on a panel for women in STEM at her daughter’s school. The girls’ enthusiasm and curiosity for science was unmistakable. “How do you design an experiment?”, “What do you like about research?”, “How do you identify mentors?”. Their ardent inquiries were nothing but reassuring. I thought, “If these girls represent the future, then the future of women in science is secure!” Enjoying this blissful moment I walked back to my research institute and was promptly jolted back to reality.

Jedd D. Wolchok, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘03-‘08) at Memorial Sloan Kettering Cancer Center, New York, and colleagues, reported that matching the size of a tumor to the body's immune response could help doctors tailor immunotherapy treatments for melanoma patients whose disease has spread.

Supporters of the Damon Runyon Cancer Research Foundation have been steadfast in their support of our work to identify and enable new generations of the most promising young scientists across the nation so that cancer research will continue to have an influx of brilliant and creative researchers with fresh ideas who are capable of making the next breakthrough against this devastating disease.

This pipeline of new talent is increasingly at risk, all the more so given the new administration’s proposal to cut the National Institutes of Health's budget for next year by 20 percent, and more recently by suggesting an immediate $1.2 billion cut.

By Michael W. Drazer, MD, Damon Runyon Physician-Scientist at The University of Chicago

Physician-scientists are uniquely positioned to identify the next generation of scientific breakthroughs and then efficiently translate these discoveries into clinically effective, life-changing therapies for people with cancer. This unique set of opportunities, however, is accompanied by a distinct set of obstacles that confront early career physician-scientists in the scientific and clinical realms. These challenges include financial debt from years of professional training, a lack of protected time for the development of scientifically sound, ambitious research programs, low salaries during years of extended training, and an increasingly unstable and unpredictable funding environment for biomedical research at the national level.

David M. Livingston, MD (Damon Runyon Board Member), of Dana-Farber Cancer Institute, Boston, has been named the 20th recipient of the Pezcoller Foundation-AACR International Award for Cancer Research. Dr. Livingston is honored for his fundamental contributions to the field of basic cancer research. His work has been pivotal to the understanding of retinoblastoma pathway of cell cycle control as well as the transcriptional co-activation function of the key regulatory proteins, p300 and CBP.

At the junction of growth and starvation stands a signaling protein called mechanistic Target of Rapamycin Complex 1 (mTORC1). Inside the cell, mTORC1 regulates metabolism, growth, protein and organelle recycling (autophagy), proliferation, and survival. When something goes wrong in the pathway, various diseases such as cancer, obesity, and type 2 diabetes, can develop.

By Yi Yin, PhD, Damon Runyon Fellow, University of Washington

The Damon Runyon Cancer Research Foundation recently asked some of our current award recipients how cancer will be prevented, diagnosed, and/or treated differently in the future. What can a future cancer patient, say 10-20 years from now, expect to experience? Their responses were fascinating, and over the next few months we will share their visions for the future on this blog.

I think cancer will be prevented, diagnosed and/or treated very differently within the next 10-20 years.

Anjana Rao, PhD (Damon Runyon Fellow ’79), and James Scott-Browne, PhD (Damon Runyon Fellow ’11-’13), at the La Jolla Institute for Allergy and Immunology, La Jolla, and colleagues, are focusing on a key issue of how tumor-fighting T cells can lose their effectiveness or become “exhausted.”  The researchers identified two proteins, NFAT and Nr4a, that can bind to the DNA of T cells and shut down their tumor-fighting activity.  Next steps will be to determine if these processes can be interfered with or reversed in ord

The Damon Runyon Cancer Research Foundation recently asked some of our current award recipients how cancer will be prevented, diagnosed, and/or treated differently in the future. What can a future cancer patient, say 10-20 years from now, expect to experience? Their responses were fascinating, and over the next few months we will share their visions for the future on this blog.

By Amanda Balboni, PhD, Damon Runyon Sohn Fellow at the Dana-Farber Cancer Institute

In the next 10-20 years, I anticipate that tumor genetic testing will become standard practice as sequencing technology becomes faster and more cost effective. This will revolutionize the way cancer is treated clinically and make personalized cancer medicine a reality. 

Don X. Nguyen, PhD (Damon Runyon Fellow ’05-’08), of Yale Cancer Center, New Haven, and colleagues, reported new findings that explain the propensity of latent lung adenocarcinoma (LUAD) to relapse. They showed that differential expression of extracellular matrix (ECM) molecules and their interacting proteins contributes to risk of relapse in distinct LUAD subtypes. One protein called hyaluronan receptor HMMR, when overexpressed, was associated with inflammation and poor prognosis.